openPR Logo
Press release

US Benign Prostatic Hyperplasia (BPH) Procedures - Development, Growth and Forecast, 2013-2023

11-16-2017 11:14 PM CET | Health & Medicine

Press release from: P&S Market Research - Pharmaceuticals

US Benign Prostatic Hyperplasia (BPH) Procedures -

Increase in the aging population in the U.S in the next few years, is expected to create high demand for BPH treatments, since the population aged 50 years and above is more prone to BPH, and therefore tend to opt for various treatments that involve the use of procedures such as TURP, TUIP and laser based treatments. According to the National Institute of Health, it has been estimated that around 14 million men in the U.S. had symptoms suggestive of BPH, which can affect 50% of men aged between 51 and 60 years of age, and up to 90% of men aged more than 80 years. With 50% of men getting affected with BPH, there is a consequent increase in the BPH procedures.

Explore Report Sample at: https://www.psmarketresearch.com/market-analysis/us-bph-procedures/report-sample

The advanced research and development activities has led to the development of technologically advanced BPH devices and therapies. Prostatic urethral lift (Urolift system) and targeted sterile water vapor therapy (Rezūm) are some of the recent technological therapies launched for BPH management. Rezūm is a minimally invasive procedure that uses steam in the treatment of enlarged prostate and is currently available in the U.S. These therapies can be performed in a clinic or at an outpatient facility, and thereby reduce the cost associated with hospital stay and surgeries.

Key player in the U.S. BPH procedures are acquiring other players to offer advanced products for BPH treatment procedures. For instance, in September 2017, Teleflex Incorporated, announced that the company has entered into definitive agreement with NeoTract, Inc. Under the terms of the agreement, Teleflex Incorporated agreed to acquire NeoTract, Inc. for a consideration of up to $1.1 billion. With this agreement, Teleflex Incorporated would be able to leverage the potential long-term benefits from NeoTracts, Inc. second generation UroLift system, which is expected to launch in the mid of 2018.

Access Detailed Report Summary on "US Benign Prostatic Hyperplasia (BPH) Procedures" at: https://www.psmarketresearch.com/market-analysis/us-bph-procedures

Some of the other key players providing products for BPH procedures in the U.S. include NxThera, Inc., Boston Scientific Corporation, Urologix, LLC., Convergent Laser Technologies.

About P&S Market Research

P&S Market Research is a market research company, which offers market research and consulting services for various geographies around the globe. We provide market research reports, industry forecasting reports, business intelligence, and research based consulting services across different industry/business verticals.

As one of the top growing market research agency, we’re keen upon providing market landscape and accurate forecasting. Our analysts and consultants are proficient with business intelligence and market analysis, through their interaction with leading companies of the concerned domain. We help our clients with B2B market research and assist them in identifying various windows of opportunity, and framing informed and customized business expansion strategies in different regions.

Contact:
Kundan
Manager – Client Partner
347, 5th Ave. #1402
New York City, NY - 10016
Toll-Free: +1-888-778-7886 (USA/Canada)
Email: enquiry@psmarketresearch.com
Web: https://www.psmarketresearch.com

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release US Benign Prostatic Hyperplasia (BPH) Procedures - Development, Growth and Forecast, 2013-2023 here

News-ID: 820797 • Views:

More Releases from P&S Market Research - Pharmaceuticals

Psoriasis Therapeutics Pipeline Analysis 2017 - Clinical Trials & Results, Patent, Designation, Collaboration, and Other Developments
Psoriasis Therapeutics Pipeline Analysis 2017 - Clinical Trials & Results, Paten …
The study analyzed that the psoriasis therapeutics pipeline comprises approximately 150 drug candidates in different stages of development. Psoriasis is a chronic inflammatory disorder that causes red patches covered with white scales on the skin. It is characterized when a person’s immune system sends defective signals which results in skin cells to grow rapidly. The body does not shed these excess skin cells and pile up on the surface of
Diabetic Foot Ulcer Therapeutics Pipeline Projects Immense Growth Ahead
Diabetic Foot Ulcer Therapeutics Pipeline Projects Immense Growth Ahead
The study analysed that the diabetic foot ulcer pipeline comprises of approximately 27 drug candidates in different stages of development. Explore Full Report Description At@ https://www.psmarketresearch.com/market-analysis/diabetic-foot-ulcers-therapeutics-pipeline-analysis Diabetic foot ulcer is a serious complication of diabetes and can be defined as the ulceration in foot along with neuropathy or peripheral artery disease of the lower limb in diabetic patients. Diabetic foot ulcer is categorized into two types namely; neuropathic foot where
Technological Advancements at Cellular and Molecular Level Strengthening the IgA Nephropathy Pipeline
Technological Advancements at Cellular and Molecular Level Strengthening the IgA …
The pipeline involves drug candidates that are being developed using specific targets such as a proliferation-inducing ligand (APRIL) and B lymphocyte stimulator (BlyS). More than three drug candidates are being developed using subcutaneous route of administration. Explore Full Report Description At@ https://www.psmarketresearch.com/market-analysis/iga-nephropathy-pipeline-analysis The study analyzed that the IgA nephropathy therapeutics pipeline comprises of 24 drug candidates in different stages of development. The report also includes epidemiology forecast for IgA Nephropathy for the
Idiopathic Pulmonary Fibrosis (IPF) Therapeutics Pipeline Analysis, 2017
Idiopathic Pulmonary Fibrosis (IPF) Therapeutics Pipeline Analysis, 2017
The study analyzed that the IPF pipeline comprised of 104 drug candidates, of which 19 drugs are in the Phase II stage of development. The lack of complete cure for IPF fuels the extensive research and development for the IPF therapeutic. There are various drugs that are being developed as novel and promising therapeutics for the treatment of IPF. Explore Full Report Description At@ https://www.psmarketresearch.com/market-analysis/idiopathic-pulmonary-fibrosis-therapeutics-market As per the findings of research, it

All 5 Releases


More Releases for BPH

Elderly Men Creating Huge Requirement for BPH Treatment Drugs and Devices
Benign prostatic hyperplasia (BPH) or prostate gland enlargement is caused due to urinary tract infections, bladder or kidney stones, prostatitis, urethral stricture, bladder or prostate cancer, and scarring in the bladder neck caused due to previous surgeries. The common signs and symptoms of BPH include frequent urination, nocturia, difficulty in initiating urination, dribble at the end of urination, and inability to empty the bladder. This disease is highly prevalent among
Benign prostatic hyperplasia: BPH drugs versus Dr Allen’s Device
The Global Treatment Market of Benign prostatic hyperplasia (BPH) was valued at $10,688.72 million in 2017 and is projected to reach $20,096.68 million by 2025 at a CAGR of 8.1% from 2018 to 2025. Thermobalancing therapy with Dr Allen’s Device was patented by the United States Patent and Trademark Office. Over a decade, thousands of men with BPH used or are using this non-invasive and side-effects free Dr Allen’s Device.
Benign Prostatic Hyperplasia (BPH) Procedures Insights, Potential Business Strat …
Increasing life expectancy and fall in the birth rates are the major reasons for rise in the aging population. The people in this category require extensive care, since they are more prone to illness due to low immunity levels and longer recovery time. Increase in the aging population in the U.S., Germany, China and India in the next few years, is expected to create high demand for BPH treatment devices,
Benign Prostatic Hyperplasia (BPH) Treatment Devices Market Trends, Technologica …
Benign Prostatic Hyperplasia (BPH) refers to an enlarged prostate gland. The prostate gland surrounds the urethra, the tube that carries urine from the bladder out of the body. Enlargement of prostate gland leads to blockage in urethra, thus causing problems during urination. It involves glandular and stromal epithelial hyperplasia, which occurs in the peri-urethral transition zone surrounding the urethra. Access Detailed Report Summary: https://www.psmarketresearch.com/market-analysis/bph-treatment-devices-market BPH is common in aging men,
Benign Prostatic Hyperplasia (BPH) And Prostate Treatment Market Industry Trends …
Benign prostatic hyperplasia (BPH) is also known as benign prostatic hypertrophy or benign prostatic obstruction. Benign prostatic hyperplasia (BPH) is a health condition in men in which the prostate gland size is enlarged than a normal. In a men whole life, prostate grows in two phases, first phase is occurs in early stage of puberty, second phase starts at the age of twenty five and it continues most of persons
Benign Prostatic Hyperplasia (BPH) And Prostate Treatment Market Opportunity Ass …
Benign prostatic hyperplasia (BPH) is also known as benign prostatic hypertrophy or benign prostatic obstruction. Benign prostatic hyperplasia (BPH) is a health condition in men in which the prostate gland size is enlarged than a normal. In a men whole life, prostate grows in two phases, first phase is occurs in early stage of puberty, second phase starts at the age of twenty five and it continues most of persons